Eli Lilly and Company (NYSE: LLY), founded in 1876 by Colonel Eli Lilly in Indianapolis, Indiana. Its diverse portfolio includes diabetes medications like Trulicity, Mounjaro, Humalog, and Basaglar; oncology drugs such as Verzenio, Cyramza, and Zepbound; and mental health treatments including Prozac, Zyprexa, and Cymbalta.
Lilly’s product line extends to immunology with Taltz and Olumiant, and other notable drugs like Emgality for migraines and Jardiance for diabetes. The company’s breakthrough in insulin production in the 1920s established its position in the diabetes market.
Eli Lilly (LLY) executed four 2:1 stock splits in 1986, 1989, 1995, and 1997. One share purchased before January 1986 would now equal 16 shares.
Key Takeaways:
- Eli Lilly’s stock shows potential to reach $8,700 by 2050, driven by breakthroughs in diabetes treatments.
- Steady 8.6% CAGR over 25 years indicates strong growth potential in pharmaceutical market leadership.
- Oncology and immunology advancements could accelerate growth beyond $3,000 mark by late 2030s.
Eli Lilly Company Profile
| Country | United States |
| Ticker Symbol | LLY |
| Exchange | NYSE |
| Founded | 1876 |
| IPO Date | 1978 |
| Industry | Drug Manufacturers – General |
| Sector | Healthcare |
| Employees | 43,000 |
| CEO | Mr. David A. Ricks |
| Website | lilly |
Eli Lilly Fundamental & Technical Data
Fundamental Data: (Data Source: marketwatch.com)
| Metric | Value |
|---|---|
| 52 Week Range | 561.65 – 972.53 |
| Market Cap | $708.38B |
| Shares Outstanding | 949.32M |
| Public Float | 850.67M |
| Beta | 0.64 |
| Rev. per Employee | N/A |
| P/E Ratio | 81.63 |
| EPS | $9.14 |
| Yield | 0.70% |
| Dividend | $1.30 |
| Ex-Dividend Date | Nov 15, 2024 |
| Short Interest | 6.62M (10/31/24) |
| % of Float Shorted | 0.78% |
| Average Volume | 3.22M |
Technical Data: (Data Source: stockanalysis.com)
| Metric | Value |
|---|---|
| Beta (5Y) | 0.48 |
| 52-Week Price Change | -7.20% |
| 50-Day Moving Average | 25.96 |
| 200-Day Moving Average | 28.37 |
| Relative Strength Index (RSI) | 56.39 |
| Average Volume (20 Days) | 1,869,053 |
Fundamentals: The stock shows strong fundamentals with a high market cap of $708.38B and healthy EPS of $9.14, though the P/E ratio of 81.63 suggests premium valuation. Low dividend yield indicates focus on growth.
Technical Analysis: The stock is trading below both 50-day and 200-day moving averages, indicating bearish trend. RSI at 56.39 shows neutral momentum, while negative 52-week price change (-7.20%) suggests underperformance.
Market Sentiment: Low short interest (0.78% of float) and moderate beta (0.64) indicate relatively low market skepticism and volatility. Volume trends are stable, suggesting normal trading activity without unusual pressure.
Eli Lilly Stock Price Prediction Tomorrow
Eli Lilly’s chart shows bearish momentum with a -3.15% decline and 3.999M volume. Current price at $786.23 faces immediate support at $777 and resistance at $800. The sharp sell-off and high volume indicate continued downward pressure. While oversold conditions might trigger a brief technical bounce, the overall sentiment appears bearish. Watch for key support level at $777, which if broken, could accelerate selling. Short-term indicators suggest caution.
Eli Lilly Stock Price Prediction Next Week
The downtrend since September from $960 highs shows persistent weakness. Price action suggests possible consolidation between $775-820 range. Volume patterns reflect sustained selling pressure with resistance at $820-840. The current technical structure indicates continued volatility with bearish bias. Key support at $775 is crucial; breaking below could trigger further declines. The stock needs to reclaim $820 to shift sentiment. Expect choppy trading within established range.
Where Will Eli Lilly Stock Be In 1, 3, 5, 7 and 10 years?
Eli Lilly’s stock shows a consistent upward trend over the next decade. Starting at a low of $770 and high of $1,130 in one year, the stock is expected to nearly double within 10 years, reaching between $1,545 and $2,345. The growth appears steady, with three-year projections ranging from $905 to $1,315, five-year estimates between $1,055 and $1,535, and seven-year forecasts from $1,245 to $1,815. These projections suggest strong investor confidence in Eli Lilly’s future performance, driven by their expanding portfolio in diabetes, oncology, and neuroscience treatments.
| Timeframe | Low Price | Average Price | High Price |
|---|---|---|---|
| 1 Year | $770.00 | $905.00 | $1,130.00 |
| 3 Years | $905.00 | $1,055.00 | $1,315.00 |
| 5 Years | $1,055.00 | $1,245.00 | $1,535.00 |
| 7 Years | $1,245.00 | $1,475.00 | $1,815.00 |
| 10 Years | $1,545.00 | $1,895.00 | $2,345.00 |
Eli Lilly Stock Price Prediction 2025
By 2025, Eli Lilly is expected to reach $1,130.00. Our analysts anticipate an 8% growth potential driven by expanding diabetes treatment portfolio. The support level might establish at $770.00, with resistance potentially reaching $1,130.00. The growing adoption of Humalog in global markets and continued success of diabetes management programs could enhance market presence. Market capitalization could reach $850 billion, while the Price-to-Earnings (P/E) Ratio may reach 150, reflecting strong investor confidence in future growth prospects.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2025 | $770.00 | $905.00 | $1,130.00 |
| Month (2025) | Low Price | High Price |
|---|---|---|
| January | $770.00 | $825.00 |
| February | $765.00 | $840.00 |
| March | $780.00 | $855.00 |
| April | $775.00 | $890.00 |
| May | $790.00 | $915.00 |
| June | $785.00 | $945.00 |
| July | $795.00 | $980.00 |
| August | $805.00 | $1,015.00 |
| September | $815.00 | $1,045.00 |
| October | $825.00 | $1,085.00 |
| November | $845.00 | $1,105.00 |
| December | $870.00 | $1,130.00 |
Read more forecast: Edwards Lifesciences Corporation (EW) Stock Price Prediction
Eli Lilly Stock Price Prediction 2026
By 2026, Eli Lilly is expected to reach $1,215.00. Our analysts project a 7.5% increase as breakthroughs in oncology research may strengthen market confidence. The support level might establish at $835.00, with resistance potentially reaching $1,215.00. Verzenio’s potential approval for additional cancer treatments and expansion of immunology pipeline might open new revenue streams.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2026 | $835.00 | $975.00 | $1,215.00 |
| Month (2026) | Low Price | High Price |
|---|---|---|
| January | $835.00 | $1,135.00 |
| February | $840.00 | $1,145.00 |
| March | $845.00 | $1,155.00 |
| April | $855.00 | $1,165.00 |
| May | $860.00 | $1,175.00 |
| June | $870.00 | $1,180.00 |
| July | $880.00 | $1,185.00 |
| August | $890.00 | $1,190.00 |
| September | $900.00 | $1,195.00 |
| October | $910.00 | $1,200.00 |
| November | $920.00 | $1,210.00 |
| December | $935.00 | $1,215.00 |
Eli Lilly Stock Price Prediction 2027
By 2027, Eli Lilly is expected to reach $1,315.00. We anticipate an 8% growth as the company’s neuroscience portfolio could expand significantly. The support level might establish at $905.00, with resistance potentially reaching $1,315.00. Advanced clinical trials in Alzheimer’s treatments and expanding applications of Cymbalta may drive market confidence.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2027 | $905.00 | $1,055.00 | $1,315.00 |
| Month (2027) | Low Price | High Price |
|---|---|---|
| January | $905.00 | $1,220.00 |
| February | $915.00 | $1,235.00 |
| March | $925.00 | $1,245.00 |
| April | $935.00 | $1,255.00 |
| May | $945.00 | $1,265.00 |
| June | $955.00 | $1,275.00 |
| July | $965.00 | $1,285.00 |
| August | $975.00 | $1,290.00 |
| September | $985.00 | $1,295.00 |
| October | $995.00 | $1,300.00 |
| November | $1,005.00 | $1,310.00 |
| December | $1,015.00 | $1,315.00 |
Eli Lilly Stock Price Prediction 2028
By 2028, Eli Lilly is expected to reach $1,420.00. Our analysts foresee a 7.8% increase driven by potential breakthroughs in autoimmune diseases. The support level might establish at $975.00, with resistance potentially reaching $1,420.00. New applications of Taltz and expansion in developing markets may boost investor confidence.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2028 | $975.00 | $1,145.00 | $1,420.00 |
| Month (2028) | Low Price | High Price |
|---|---|---|
| January | $975.00 | $1,320.00 |
| February | $985.00 | $1,340.00 |
| March | $995.00 | $1,355.00 |
| April | $1,015.00 | $1,365.00 |
| May | $1,025.00 | $1,375.00 |
| June | $1,035.00 | $1,385.00 |
| July | $1,045.00 | $1,390.00 |
| August | $1,055.00 | $1,395.00 |
| September | $1,065.00 | $1,400.00 |
| October | $1,075.00 | $1,410.00 |
| November | $1,085.00 | $1,415.00 |
| December | $1,095.00 | $1,420.00 |
Eli Lilly Stock Price Prediction 2029
By 2029, Eli Lilly is expected to reach $1,535.00. We project an 8.1% growth as advances in diabetes treatment technologies could reshape market dynamics. The support level might establish at $1,055.00, with resistance potentially reaching $1,535.00. Enhanced patient support programs and strategic investments in digital health solutions may drive value.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2029 | $1,055.00 | $1,245.00 | $1,535.00 |
| Month (2029) | Low Price | High Price |
|---|---|---|
| January | $1,055.00 | $1,425.00 |
| February | $1,065.00 | $1,445.00 |
| March | $1,075.00 | $1,455.00 |
| April | $1,085.00 | $1,465.00 |
| May | $1,095.00 | $1,475.00 |
| June | $1,105.00 | $1,485.00 |
| July | $1,115.00 | $1,495.00 |
| August | $1,125.00 | $1,505.00 |
| September | $1,135.00 | $1,515.00 |
| October | $1,145.00 | $1,525.00 |
| November | $1,155.00 | $1,530.00 |
| December | $1,165.00 | $1,535.00 |
Eli Lilly Stock Price Prediction 2030
By 2030, Eli Lilly is expected to reach $1,665.00. Our analysts anticipate a 7.8% growth potential as the company’s diagnostics and oncology portfolios could reach new milestones. The support level might establish at $1,145.00, with resistance potentially reaching $1,665.00. The maturation of the cardiovascular disease pipeline and expansion of healthcare professional education programs may create additional value streams.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2030 | $1,145.00 | $1,355.00 | $1,665.00 |
| Month (2030) | Low Price | High Price |
|---|---|---|
| January | $1,145.00 | $1,540.00 |
| February | $1,165.00 | $1,555.00 |
| March | $1,175.00 | $1,570.00 |
| April | $1,185.00 | $1,585.00 |
| May | $1,195.00 | $1,595.00 |
| June | $1,205.00 | $1,605.00 |
| July | $1,215.00 | $1,615.00 |
| August | $1,225.00 | $1,625.00 |
| September | $1,235.00 | $1,635.00 |
| October | $1,245.00 | $1,645.00 |
| November | $1,255.00 | $1,655.00 |
| December | $1,265.00 | $1,665.00 |
Read more forecast: Exelon Corporation (EXC) Stock Price Prediction
Eli Lilly Stock Price Prediction 2031
By 2031, Eli Lilly is expected to reach $1,815.00. Our analysts project a 9% growth as the company’s immunology research could yield groundbreaking treatments. The support level might establish at $1,245.00, with resistance potentially reaching $1,815.00. Advancements in neuroscience treatments and expanded applications of existing medications may strengthen revenue streams.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2031 | $1,245.00 | $1,475.00 | $1,815.00 |
Eli Lilly Stock Price Prediction 2032
By 2032, Eli Lilly is expected to reach $1,975.00. We anticipate an 8.5% increase driven by potential breakthroughs in viral infections research. The support level might establish at $1,345.00, with resistance potentially reaching $1,975.00. Enhanced patient support programs and digital health integration could boost market confidence.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2032 | $1,345.00 | $1,605.00 | $1,975.00 |
Eli Lilly Stock Price Prediction 2033
By 2033, Eli Lilly is expected to reach $2,155.00. Our analysts foresee a 9% growth as advances in diabetes management technologies could transform treatment approaches. The support level might establish at $1,445.00, with resistance potentially reaching $2,155.00. Expansion of Trulicity applications may drive market value.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2033 | $1,445.00 | $1,745.00 | $2,155.00 |
Eli Lilly Stock Price Prediction 2034
By 2034, Eli Lilly is expected to reach $2,345.00. We project an 8.8% increase as oncology research breakthroughs could reshape treatment paradigms. The support level might establish at $1,545.00, with resistance potentially reaching $2,345.00. Advanced applications of Verzenio may enhance market position.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2034 | $1,545.00 | $1,895.00 | $2,345.00 |
Eli Lilly Stock Price Prediction 2035
By 2035, Eli Lilly is expected to reach $2,545.00. Our analysts anticipate an 8.5% growth potential through expanded applications in autoimmune diseases. The support level might establish at $1,645.00, with resistance potentially reaching $2,545.00. New generations of Taltz treatments and breakthrough therapies could enhance market value.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2035 | $1,645.00 | $2,045.00 | $2,545.00 |
Eli Lilly Stock Price Prediction 2036
By 2036, Eli Lilly is expected to reach $2,765.00. We project an 8.6% increase as advancements in cardiovascular treatments could open new markets. The support level might establish at $1,745.00, with resistance potentially reaching $2,765.00. Enhanced diagnostic tools and precision medicine approaches may drive growth.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2036 | $1,745.00 | $2,205.00 | $2,765.00 |
Eli Lilly Stock Price Prediction 2037
By 2037, Eli Lilly is expected to reach $2,995.00. Our analysts foresee an 8.3% growth driven by innovations in neuroscience therapeutics. The support level might establish at $1,845.00, with resistance potentially reaching $2,995.00. Advanced research in Alzheimer’s treatments could strengthen market position.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2037 | $1,845.00 | $2,370.00 | $2,995.00 |
Eli Lilly Stock Price Prediction 2038
By 2038, Eli Lilly is expected to reach $3,245.00. We anticipate an 8.4% increase through expanded immunology research applications. The support level might establish at $1,945.00, with resistance potentially reaching $3,245.00. Next-generation diabetes management solutions may boost investor confidence.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2038 | $1,945.00 | $2,545.00 | $3,245.00 |
Eli Lilly Stock Price Prediction 2039
By 2039, Eli Lilly is expected to reach $3,515.00. Our analysts project an 8.3% growth as breakthrough therapies in viral infections could reshape treatment protocols. The support level might establish at $2,045.00, with resistance potentially reaching $3,515.00. Advanced patient care technologies and global market expansion may drive value.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2039 | $2,045.00 | $2,730.00 | $3,515.00 |
Eli Lilly Stock Price Prediction 2040
By 2040, Eli Lilly is expected to reach $3,815.00. Our analysts anticipate an 8.5% growth driven by revolutionary breakthroughs in oncology and neuroscience. The support level might establish at $2,245.00, with resistance potentially reaching $3,815.00. Integration of artificial intelligence in drug discovery and personalized patient support programs could transform treatment outcomes.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2040 | $2,245.00 | $2,980.00 | $3,815.00 |
| Month (2040) | Low Price | High Price |
|---|---|---|
| January | $2,245.00 | $3,520.00 |
| February | $2,285.00 | $3,555.00 |
| March | $2,325.00 | $3,595.00 |
| April | $2,365.00 | $3,625.00 |
| May | $2,405.00 | $3,655.00 |
| June | $2,445.00 | $3,685.00 |
| July | $2,485.00 | $3,715.00 |
| August | $2,525.00 | $3,735.00 |
| September | $2,565.00 | $3,755.00 |
| October | $2,605.00 | $3,775.00 |
| November | $2,645.00 | $3,795.00 |
| December | $2,685.00 | $3,815.00 |
Read more forecast: Cardano (ADA) Price Prediction
Eli Lilly Stock Price Prediction 2050
By 2050, Eli Lilly is expected to reach $8,700.00. We project substantial growth through revolutionary advancements in diabetes, immunology, and precision medicine. The support level might establish at $5,245.00, with resistance potentially reaching $8,700.00. Next-generation therapeutics and global healthcare solutions could establish new industry standards.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2050 | $5,245.00 | $6,925.00 | $8,700.00 |
| Month (2050) | Low Price | High Price |
|---|---|---|
| January | $5,245.00 | $7,800.00 |
| February | $5,445.00 | $7,950.00 |
| March | $5,645.00 | $8,050.00 |
| April | $5,845.00 | $8,150.00 |
| May | $6,045.00 | $8,250.00 |
| June | $6,245.00 | $8,350.00 |
| July | $6,445.00 | $8,450.00 |
| August | $6,645.00 | $8,500.00 |
| September | $6,845.00 | $8,550.00 |
| October | $7,045.00 | $8,600.00 |
| November | $7,245.00 | $8,650.00 |
| December | $7,445.00 | $8,700.00 |
Who are the Major Competitors of Eli Lilly & Co
| Company Name | Market Cap (USD) | Enterprise Value (USD) | Dividend % | YTD Return |
|---|---|---|---|---|
| Eli Lilly and Company (LLY) | 671.90B | 699.14B | 0.70% | +28.01% |
| Johnson & Johnson (JNJ) | 370.77B | 386.23B | 3.22% | -1.75% |
| AbbVie Inc. (ABBV) | 291.56B | 355.64B | 3.98% | +6.47% |
| Merck & Co., Inc. (MRK) | 243.63B | 267.23B | 3.20% | -11.66% |
| Pfizer Inc. (PFE) | 140.54B | 203.57B | 6.77% | -13.86% |
| Bristol-Myers Squibb (BMY) | 114.02B | 157.10B | 4.27% | +9.57% |
| Zoetis Inc. (ZTS) | 79.02B | 84.08B | 0.99% | -11.26% |
| Royalty Pharma (RPRX) | 15.14B | 21.42B | 3.27% | -8.51% |
| Jazz Pharmaceuticals (JAZZ) | 7.35B | 10.94B | N/A | -1.10% |
| Corcept Therapeutics (CORT) | 5.43B | 4.89B | N/A | +59.58% |
| Perrigo Company plc (PRGO) | 3.66B | 7.18B | 4.12% | -16.69% |
Eli Lilly & Co Balance Sheet Report
Eli Lilly’s 2023 balance sheet reveals significant growth, with total assets reaching $64.01 billion, up from $49.49 billion in 2022. This expansion was matched by increased liabilities, rising to $53.14 billion from $38.71 billion.
Total debt grew substantially to $25.23 billion, while net debt increased to $22.41 billion. The company’s working capital turned negative at -$1.57 billion, potentially indicating short-term liquidity challenges.
Despite asset growth, Eli Lilly’s total equity remained relatively stable at $10.86 billion. Net tangible assets worsened to -$1.07 billion, suggesting a high proportion of intangible assets.
Overall, the balance sheet reflects a year of expansion for Eli Lilly, marked by increased assets and liabilities. This growth strategy may present both opportunities and financial risks for the company moving forward.
Conclusion
From 2025 to 2050, Eli Lilly’s stock price shows remarkable growth from $1,130.00 to $8,700.00. With a Compound Annual Growth Rate (CAGR) of 8.6% over this 25-year period, the company demonstrates strong potential in the pharmaceutical sector. The expansion from a market capitalization of $850 billion in 2025 to its 2050 valuation reflects Eli Lilly’s success in diabetes, oncology, immunology, and neuroscience therapeutic areas.
FAQs
1. What is the forecast for Eli Lilly stock?
Our analysis projects steady growth for Eli Lilly stock, with prices expected to reach $1,130.00 by 2025, $1,665.00 by 2030, and $3,815.00 by 2040. The company’s strategic focus on diabetes, oncology, and immunology therapies supports a long-term price target of $8,700.00 by 2050. With a CAGR of 8.6% over 25 years, the stock shows strong potential for sustained value appreciation.
2. Can Eli Lilly stock reach $1,000?
Based on our forecast, Eli Lilly stock could surpass $1,000 by early 2026, reaching a high of $1,215.00. The growth is supported by expansion in neuroscience research and patient support programs. Market data suggests a steady climb, with support levels strengthening from $770.00 in 2025 to $835.00 in 2026, indicating sustainable momentum above the $1,000 mark.
3. Can Eli Lilly stock reach $2,000?
Our analysis indicates Eli Lilly stock could reach $2,000 by 2033, with projections showing a high of $2,155.00. The company’s advancements in diabetes management and oncology treatments support this milestone. Monthly price movements show consistent growth, with strong support levels and resistance points suggesting steady progression toward and beyond the $2,000 threshold.
4. Can Eli Lilly stock reach $3,000?
The forecast shows Eli Lilly reaching $3,000 by 2037, with a projected high of $2,995.00. Innovations in neuroscience therapeutics and Alzheimer’s treatments could drive this growth. Market analysis indicates support levels strengthening from $1,845.00, with average prices consistently trending upward through the $3,000 mark by late 2037.
5. Can Eli Lilly stock reach $7,000?
Projections indicate Eli Lilly could surpass $7,000 by late 2050, reaching $8,700.00. This growth is supported by revolutionary advancements in precision medicine and immunology. Monthly forecasts show progressive increases, with support levels rising from $5,245.00 to $7,445.00 throughout 2050, indicating strong potential for reaching and exceeding the $7,000 mark.
6. Is Eli Lilly a “buy”, “hold” or “sell”?
Given the projected growth from $1,130.00 in 2025 to $8,700.00 by 2050, with consistent support level increases and steady resistance level progression, Eli Lilly presents as a strong buy opportunity. The company’s expanding portfolio in diabetes, oncology, and neuroscience, combined with an 8.6% CAGR over 25 years, suggests robust long-term value potential.
Disclaimer:
The stock price predictions provided herein are based on historical data, current market trends, and analysis. However, past performance does not guarantee future results. Stock markets are inherently volatile and subject to numerous economic, political, and market factors that can cause rapid and unpredictable fluctuations in stock prices. The information provided is for educational and informational purposes only and should not be construed as financial advice. It is strongly recommended that you consult with a qualified financial advisor before making any investment decisions. Invest responsibly and consider your individual financial situation, risk tolerance, and investment objectives before acting on any information provided.
